Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 971 to 980 of 1000 total matches.

Aliskiren (Tekturna) for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Apr 09, 2007  (Issue 1258)
., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
Aliskiren (ah LIS ker in; Tekturna - Novartis), the first direct renin inhibitor, has been approved by the FDA for treatment of hypertension. It is indicated for oral use either as monotherapy or in combination with other antihypertensive agents.
Med Lett Drugs Ther. 2007 Apr 9;49(1258):29-31 |  Show IntroductionHide Introduction

Expanded Table: Some Vaccines for Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
Populations: recommended 50.50 44.80 Measles, Mumps, Rubella (MMR) M-M-R II (Merck) Priorix (GSK) 0.5 mL ...
Med Lett Drugs Ther. 2022 Oct 17;64(1661):e170-3 |  Show IntroductionHide Introduction

Cancer Screening

   
Treatment Guidelines from The Medical Letter • Dec 01, 2012  (Issue 124)
The American Urological Association recommends beginning screening at age 40.17 1. R Siegel et al. Cancer ...
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may improve outcomes. Screening tests for some common cancers are reviewed below.
Treat Guidel Med Lett. 2012 Dec;10(124):87-94 |  Show IntroductionHide Introduction

Vaccines for Travelers

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018  (Issue 1560)
is available as a live-attenuated vaccine in combination with mumps and rubella (MMR; M-M-R-II) or with mumps ...
Persons planning to travel outside the US should be up to date on routine vaccines and, depending on their destination, duration of travel, and planned activities, may also receive certain travel-specific vaccines. Tickborne encephalitis and dengue vaccines, which are not available in the US, are reviewed in a separate article available online. Detailed advice for travel to specific destinations is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for administration of vaccines as part of routine...
Med Lett Drugs Ther. 2018 Nov 19;60(1560):185-92 |  Show IntroductionHide Introduction

Liraglutide (Victoza) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2010  (Issue 1335)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Jordan W. Smoller, M.D., Sc.D ...
Liraglutide (Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can be used alone or in addition to oral antidiabetic drugs such as metformin (Glucophage, and others) or glimepiride (Amaryl, and others). Liraglutide is not recommended for first-line therapy and is not approved for use with insulin.
Med Lett Drugs Ther. 2010 Apr 5;52(1335):25-7 |  Show IntroductionHide Introduction

Insect Repellents

   
The Medical Letter on Drugs and Therapeutics • Jul 12, 2021  (Issue 1628)
Aedes aegypti mosquitoes. Trans R Soc Trop Med Hyg 2020; 114:687. 13. JH Diaz. Chemical and plant ...
The Centers for Disease Control and Prevention (CDC) and the Environmental Protection Agency (EPA) recommend using insect repellents to prevent infections transmitted by mosquitoes and ticks. Insect repellents applied to exposed skin should be used in conjunction with other preventive measures such as wearing pants and long-sleeved shirts and avoiding outdoor activities during peak mosquito-biting times. Mosquitoes can transmit diseasecausing pathogens, including Zika, chikungunya, dengue, West Nile, eastern equine encephalitis, and yellow fever viruses, and the malaria parasite....
Med Lett Drugs Ther. 2021 Jul 12;63(1628):109-12 |  Show IntroductionHide Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
: a systematic review and meta-analysis. JAMA 2021; 325:2357. 18. R Croop et al. Zavegepant nasal spray ...
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96   doi:10.58347/tml.2023.1678a |  Show IntroductionHide Introduction

Drugs for Thyroid Disorders

   
Treatment Guidelines from The Medical Letter • Aug 01, 2009  (Issue 84)
., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Treat Guidel Med Lett. 2009 Aug;7(84):57-64 |  Show IntroductionHide Introduction

Cardiovascular Drugs in the ICU

   
Treatment Guidelines from The Medical Letter • Dec 01, 2002  (Issue 4)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Elizabeth Stephens, M.D ...
Ever-increasing specialization has made it difficult for many physicians to keep up with therapeutic standards in intensive-care units (ICUs). This issue of Treatment Guidelines offers current recommendations for use of cardiovascular drugs in the ICU for treatment of hypertensive emergencies; shock, cardiac arrest or decompensated heart failure; and ventricular arrhythmias.
Treat Guidel Med Lett. 2002 Dec;0(4):19-24 |  Show IntroductionHide Introduction

Drugs for Benign Prostatic Hyperplasia

   
The Medical Letter on Drugs and Therapeutics • May 02, 2022  (Issue 1649)
outlet obstruction. J Urol 2013; 190:1320. 36. R MacDonald et al. Serenoa repens monotherapy for benign ...
About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to prevent disease progression and complications such as acute urinary retention. The American Urologic Association's guidelines for treatment of BPH were recently updated.
Med Lett Drugs Ther. 2022 May 2;64(1649):65-9 |  Show IntroductionHide Introduction